Investor Presentaiton

IDE161 shows Selective Sensitivity in HRD and Differentiation from PARPI 1.5 1 0.5 -0.5 0 IDE161 Sensitivity Profile in Cell Panel Cellular response profiles reveal mechanistic associations with PARGI sensitivity IDC161 Cellular IC50 (log 10 μM) IDE161 Selective Sensitivity vs PARPI HRD cell lines are selectively sensitive 5 4.5 4 to IDE161 versus PARPI PARPI Responsive Models IDE161 Sensitivity in HRD Breast Cancer Response to IDE161 is strongly associated with HRD status in Breast Cancer Cell Lines Cellular antiproliferative response to IDE161 stratified by HRR status Tumor Cell Model Breast Cervical Gastric 0.5 Ovary Pancreatic Prostate 0.0 (Breast Cancer: n=24, Wilcoxon pval=0.008) -1 -1.5 -2 -2.5 314 cell lines across 31 lineages PARGI IDE 161 IC50 (μM) 3.5 نه 5 2 1.5 IDE161 PARGI Responsive Models 1 include HRD, replication stress, nucleotide Top predictive response biomarkers* excision repair and parylation cycle * Based on univariate and multivariate pan-cancer and lineage-specific molecular feature analysis 0.5 0 0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 PARPI Niraparib IC50 (μM) 32 IDEAYA Data: AACR 2023, D. Munoz et al. Log10(IC50) -0.5 -1.0- Mutation Status CHEK2 ⚫ non-HRR -1.5 ⚫ BRCA2 CHEK1, BRCA2 -2.0 • ATM BRCA1, BRCA2 BRCA1 Wild-Type Mutant* *HRR mutation status assigned according Foundation Medicine HRR gene panel: ATM, BRCA1, BRCA2, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D, RAD54L IDEA A BIOSCIENCES

View entire presentation